AFT制药公司在2025年上半年收入增长33%,利润已上市,并保持全年展望。 AFT Pharmaceuticals grew revenue 33% in first half of 2025, posted profit, and maintained full-year outlook.

据AFT制药公司报告,2025年上半年收入增长33%,达到1.149亿美元,这是澳大利亚强劲业绩和国际市场扩大(包括海外销售增长133%)驱动的连续第十个增长期。 AFT Pharmaceuticals reported a 33% revenue increase to $114.9 million for the first half of 2025, marking its 10th consecutive growth period, driven by strong performance in Australia and expanding international markets, including a 133% rise in overseas sales. 该公司的利润为270万美元,扭转了上一年的亏损,EBITDA达到660万美元。 The company posted a $2.7 million profit, reversing a prior-year loss, with EBITDA reaching $6.6 million. 尽管研发成本上升,净债务略高,但AFT维持其全年利润指导,并重申到27财政年度达到3亿美元收入的目标。 Despite rising R&D costs and slightly higher net debt, AFT maintained its full-year profit guidance and reaffirmed its goal to reach $300 million in revenue by FY27. 该公司在美国继续扩大,拥有两个经批准的药物变种,并受益于减少潜在关税风险的当地制造伙伴关系。 The company continues to expand in the U.S., where it holds two approved drug variants and benefits from a local manufacturing partnership that mitigates risks from potential tariffs.